Wang Chrong-Reen, Yang Chao-Chun
Department of Internal Medicine Department of Dermatology, National Cheng Kung University Hospital, Tainan, Taiwan.
Medicine (Baltimore). 2018 Jun;97(25):e11053. doi: 10.1097/MD.0000000000011053.
Polyarteritis nodosa (PAN) is a difficult-to-treat rheumatology disorder, and biologic agents have been used in such patients with a treatment failure or the disease relapse.
We report a 42-year-old male Han Chinese who received adalimumab (ADA) alone during his vasculitis relapse, manifesting with weight loss, ankle arthritis, testicular inflammation and new-onset hypertension. Under the ADA 40 mg biweekly subcutaneous injection, there were the disappearance of clinical activity and no disease flares with a follow-up period of 26 months.
The clinical observation in this patient suggests a potential efficacy of ADA therapy in controlling the disease activity of PAN.
结节性多动脉炎（PAN）是一种难以治疗的风湿性疾病，生物制剂已被用于治疗失败或疾病复发的此类患者。
我们报告一名42岁汉族男性，在血管炎复发期间单独接受阿达木单抗（ADA）治疗，表现为体重减轻、踝关节关节炎、睾丸炎和新发高血压。在每两周皮下注射40毫克ADA的治疗下，临床活动消失，随访26个月无疾病复发。
该患者的临床观察表明ADA治疗在控制PAN疾病活动方面具有潜在疗效。
